VYZULTA® has a demonstrated safety
and tolerability profile

Results from two Phase 3 controlled clinical trials (pooled analysis)1†

  • The most common ocular adverse reactions observed in patients treated with VYZULTA® were:
  • – conjunctival hyperemia (6%)
  • – eye irritation (5%)
  • – eye pain (4%)
  • – instillation site pain (2%)
  • Approximately 0.7% of patients discontinued therapy due to ocular adverse reactions
    including ocular hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival
    conjunctivitis, vision blurred, punctate keratitis and foreign body sensation
  • 1.4% (11 subjects) in the VYZULTA® group had at least 1 ocular TEAE in the study eye
    leading to discontinuation
  • The most common ocular TEAE in the study eye for subjects treated with VYZULTA® leading to discontinuation was ocular hyperemia (0.2% of subjects)

VYZULTA® demonstrated durable efficacy in lowering IOP and
a tolerable safety profile with ocular effects comparable to those of
the first-line agent latanoprost and no significant systemic effects.